

## CURRICULUM VITAE OF GIUSEPPE MANCIA

### INDEX

- 1) GENERAL INFORMATION
- 2) PAST POSITIONS
- 3) MAIN ACADEMICAL/HOSPITAL APPOINTMENTS
- 4) PAST/PRESENT MEMBERSHIP OF PROFESSIONAL SOCIETIES
- 5) EXECUTIVE ROLE IN PROFESSIONAL SOCIETIES
- 6) AWARDS/HONORS
- 7) MAIN INVITED LECTURES
- 8) OTHER SELECTED INVITED LECTURES
- 9) JOURNAL SUPPLEMENTS
- 10) BOOKS/MONOGRAPHS (EDITOR)
- 11) CURRENT/PAST MAJOR EDITORIAL BOARD PARTICIPATION
- 12) MAJOR RESEARCH INTERESTS/RESEARCH AREAS
- 13) BIBLIOMETRIC DATA
- 14) MAIN SCIENTIFIC CONTRIBUTIONS

### 1. GENERAL INFORMATION

<u>Name</u>	Giuseppe Mancia
<u>Place/Date of birth</u>	Carrara, July 26 1940
<u>Citizenship</u>	Italian

#### Current Positions

- Emeritus Professor, Ministry of Scientific Research and University, Rome and Milano-Bicocca University, Milan
- President, Foundation "Ricerca e Innovazione su Ipertensione e Protezione Cardiovascolare", Milan, Italy
- President, Foundation of the European Society of Hypertension, Zürich, Switzerland
- Head, Hypertension Center, Verano Brianza (Policlinico di Monza)
- Chairman (since 2008), Joint Board of the Italian Scientific Societies for Cardiovascular Prevention

#### Degrees/Diplomas

1958: B.S.Arts (cum laude)

Liceo Classico, Teramo, Italy

1964: M.D. (cum laude)	University of Siena Medical School
1967: Diploma as Specialist in Cardiology and Rheumatic diseases (cum laude)	University of Siena, Graduate School of Cardiology
1971: Libera Docenza (PhD) in Physiology	Ministry of Scientific Research and University, Italy
1972 Diploma, Educational Council for Foreign Medical Graduates	Public Health Service, USA

## **2. Past Positions**

- 1965-1966 Fellow, National Research Council, Dpt Internal Medicine, University of Siena, Medical School
- 1966-1969 Fellow, National Research Council, Dpt Internal Medicine, University of Milan, Medical School
- 1969-1980 Assistant Professor of Medicine, Dpt of Internal Medicine, University of Milan. Medical School
- 1972-1974 Post-Graduate Fellow ,Public Health Service, USA
- 1972-1974 Research Associate, Mayo Clinic and Foundation, Rochester, USA
- 1975 Resident in Cardiology, Dpt Cardiology, Virginia Commonwealth University, Richmond, USA
- 1975-1981 Chief Investigator, Institute of Cardiovascular Research, University of Milan
- 1981-1985 Associate Professor of Medicine, Dpt Internal Medicine, University of Milan. Medical School
- 1986-1991 Full Professor of Medicine, Chair of Semeiotica Medica, University of Milan, Medical School
- 1991-1998 Full Professor of Medicine, Chair of Internal Medicine (Clinica Medica), S. Gerardo Hospital ,Monza, University of Milan, Medical School
- 1999-2012 Full Professor of Medicine, Chair of Internal Medicine (Clinica Medica), S. Gerardo Hospital, Monza, University of Milano-Bicocca, Medical School

## **3. Main Academic/Hospital Appointments**

- 1998-2012 Chairman Hospital Department of Medicine, S. Gerardo Hospital, Monza
- 1999-2006 Chairman, University Department of Clinical Medicine, Prevention and Biotechnologies, University of Milano-Bicocca, Medical School
- 1999-2006 Director, Post-graduate School of Internal Medicine, University of Milano-Bicocca
- 2006-2009 Director, Post Graduate School of Cardiology, University of Milano-Bicocca
- 2009-2012 Director, Post Graduate School of Emergency Medicine, University of Milano-Bicocca
- 2003-2008 Director, Master in Transplant Medicine, University of Milano-Bicocca
- 2007-2012 Director, Master in Electrophysiology and Cardiac Electrical, University of Milano-Bicocca
- 1999-2012 Director, Interuniversity Center (Universities of Milano, Milano-Bicocca and Pavia) for Clinical Physiology and Hypertension
- 2002-2006 Member, Academic Senate, University of Milano-Bicocca

## **4. PAST/PRESENT MEMBERSHIP IN PROFESSIONAL SOCIETIES**

- European Society of Hypertension (ESH), Honorary Member
- International Society of Hypertension (ISH)
- European Society of Cardiology (ESC), Fellow
- European Society of Clinical Investigation
- High Blood Pressure Research Council, AHA
- Royal Society of Medicine, London
- Royal Society of Physicians and Surgeons, Edimburgh
- American Heart Association (Council on Circulation)
- Società Italiana per l'Ipertensione Arteriosa
- Society of Behavioural Medicine, Honorary member
- Società Italiana di Medicina Interna
- Società Italiana di Cardiologia
- Estonian Society of Hypertension , Honorary member
- American Society of Behavioural Medicine, Honorary member
- Clinical Autonomic Research Society, UK, Honorary member
- High Blood Pressure Council of Australia, Honorary member
- Hellenic Society of Hypertension, Honorary member
- Hungarian Society of Hypertension, Honorary member
- Spanish Society of Hypertension and Hypertension League, Honorary member
- Finnish Society of Hypertension, Honorary member
- Argentinian Society of Hypertension, Honorary member

- Polish Society of Hypertension, Honorary member
- British Society of Hypertension, Honorary member
- Turkish Society of Hypertension and Atherosclerosis , Honorary member
- German Hypertension League, Honorary member
- Lebanese Hypertension League, Honorary Member
- Peruvian Society of Cardiology, Honorary member
- Romanian Hypertension Society, Honorary member
- Japanese Circulation Society, Honorary Member
- Latin-American Hypertension Society, Honorary Member
- Premio Sapio Academy, Honorary Member
- Renin Academy (Directory Board)

## 5. EXECUTIVE ROLE IN PROFESSIONAL SOCIETIES

- 1978-1982 Member, Scientific Council, European Society of Clinical Investigation. President (1980-1982)
- 1978-1986 Member, Steering Committee of the European Blood Pressure Group
- 1982-1992 Member, Executive Scientific Council of the International Society of Hypertension (ISH). Secretary (1984-1988), President (1988-1990)
- 1986-1991 Member, Executive Scientific Committee of the European Society of Cardiology (ESC)
- 1994-1996 Chairman, Working Group on Hypertension and the Heart of ESC
- 1994-2000 Chairman, ISH Forum of National Hypertension Societies
- 1994-2002 Executive Officer, ISH Hypertension News
- 1996-2008 Member (ex-officio), Executive Scientific Council of the American Society of Hypertension
- 1996-1999 Member, Scientific Council Italian Society of Hypertension – President (1998-1999)
- 1989-2003 Member, ESH Executive Scientific Council–Vice President(1997-1999),President(1999-2001)
- 2000-2008 Chairman, Advisory Board on Hypertension Specialisti of ESH
- 2003-present Chairman, Educational Committee of ESH
- 2002-2005 Member,UEMS Steering Committee(Union European Medical Specialists),Cardiology Section.
- 2013-present President, Foundation of ESH, Zürich
- 2012-present President, Foundation Ricerca e Innovazione su Ipertensione e Prevenzione Cardiovascolare
- 2005-2008 Member, Scientific Council; of the Italian Society of Cardiovascular Prevention (SIPREC)
- 1997 Member, WHO/ISH “Ad hoc” Subcommittee on Calcium Antagonists
- 1997 Member, Committee on Hypertension and Diabetes of the International Diabetes Federation
- 1990 Honorary President, ISH Meeting, Montreal
- 2002 Chairman, Scientific Committee, ISH/ESH Meeting, Prague
- 2004 Chairman, Scientific Committee, ISH Meeting, San Paulo
- 2014 Honorary President, ESH/ISH Meeting, Athens
- 2020 Honorary President, ESH/ISH Meeting, Glasgow
  
- 2001-2009 Chairman, Scientific/Organizing Committee of all ESH Meetings (10) held biannually in Milan,
- 2002-2006 Chairman, SNS International Working Group
- 1993,1998 Member, Task Force for WHO/ISH Hypertension Guidelines (Writing Committee in 1998)
- 1995,2000 Member, Award Committee of ESH
- 2001-present Member, Award Committee of ESH
- 1998,2003 Member, Task Force for CV Prevention Guidelines, ESC
- 2000-present Member, Scientific Committee of the Lorenzini Foundation
- 2003,07,09,13,18 Chairman, Task Force for ESH/ESC Hypertension Guidelines
- 2009, 2013 Chairman, Task Force on Cardiovascular Drugs of the World Heart Federation
- 1994-2000 Member, Advisory Committee of the Heidelberg High Blood Pressure Institute
- 1988-1992 Member, Advisory Research Grant Board of ESC
- 1986-2003 Member, WHO/ISH Liaison Committee
- 2000-2005 Member, Joint European Societies Cardiovascular Diseases Prevention Committee
- 1993,98,03 Member, Task Force, European Scientific Societies for CV Disease (Writing Committee)
- 2005-2009 Member, International Renin Academy
- 2000-present Member, Consiglio Esecutivo Fondazione Italiana Cuore
- 2007-present Member, Gruppo 2003 (Italian Highly Cited Investigators, Thompson Reuters)
- 2007-2011 Member, ICMA (International Cardiovascular & Metabolic Academy)
- 2006-present Member, Medical Advisory Board, International Society of Nephrology
- 2008-present Chairman of the Joint Board of the Italian Scientific Societies for Cardiovascular Prevention

## 6. AWARDS/HONORS

- 1964 - First Price Lepetit per the best Doctoral Thesis (University of Siena)
- 1972 - NATO fellowship for biomedical research ( Classified first on national basis)
- 1972 - Winner of one of the four Fellowships of the US Public Health Service for Italy
- 1973 - Scientific Productivity Price of the University of Milan
- 1977 – Scientific Productivity Price of the University of Milan
- 1981 – Scientific Productivity Price of the University of Milan
- 2008 - Gold Medal of the Lorenzini Foundation
- 2008 - Degree Honoris Causa in Medicine, University of Gdansk (Gdansk)
- 2006 - Franz Volhard Award, ISH (Fukuoka)
- 2001 - Invernizzi Award for Medicine
- 2001 - Honorary Membership, Academy of Science of Cordoba (Argentina)
- 2000 - Life Achievement Research Award of the Italian Society of Hypertension
- 2000 - International Arrigo Recordati Prize
- 2000 - Talal Zein Foundation Award, Mediterranean Society of Cardiology and Cardiac Surgery
- 2004 – Official Guest, Polish Academy of Science
- 1998 - Spinoza Honorary Professorship, University of Amsterdam
- 1998 - Bjorn Folkow Award, ESH
- 1996 - Merck Sharp & Dohme (now Tigersted) Award, ISH (Glasgow)
- 1992 - Wright Award, High Blood Pressure Council of Australia
- 1992 - Nomination as Lecturer of the Year, Belgian Universities and Hypertension League
- 1990 - Heymans Award, International Society of Pharmacology
- 2000 - Honorary Professorship, University of Cordoba
- 1996 - Merk Frosst Lecture and Award of the Canadian Society of Medicine
- 2002 - Saeb Salem Memorial Award for Educational Achievements and Medicine (Lebanon Society of Cardiology)
- 2002 - Robert Tigersted Award & Lecture of the Finnish Hypertension Society
- 2009 - Hariri Memorial Award, Lebanon Hypertension Society
- 2011 - Honorary Citizenship, City of Rosario
- 2012 - Honorary Degree in Medicine, University Carol Davila (Bucharest)
- 2013 - Gavras Life Achievement Award, Hellenic Society of Hypertension
- 2013 - Professor Emeritus, University of Milano-Bicocca (Ministry of University& Scientific Research)
- 2014 - Rosa Camuna Award ( Highest Award of the Lombardy Region)
- 2014 - Honorary Degree, (Doctor of Science), University of Glasgow
- 2014 - Commander of the Order of the Italian Republic
- 2015 - Awarded as one of the hundred Italian Excellences in various areas of human activities (Rome)
- 2015 – Editor, Compendium on Hypertension, Circulation Research (see below)
- 2016 – Population Health Lecture, Mac Master University , Hamilton (Canada)
- 2018 – Member of the European Academy of Science
- 2019 – Editor, Compendium on Hypertension, Circulation Research (see below)
- 2019 – P Sleight Award for excellence in clinical hypertension research of the World Hypertension League
- 2019 – A Zanchetti Life Achievement Award of the European Society of Hypertension
- 2019 – Honorary citizenship, City of Mar de la Plata

## 7. MAIN INVITED LECTURES

- 1985 State-of-the-Art Lecture, International Soc Cardio Pharmac, Geneva
- 1986 State-of-the-Art Lecture, International Congress Phys Sci, Vancouver
- 1986 State-of-the-Art Lecture, American Soc Behavioral Medicine, S Francisco
- 1988 Key-note Lecture, Clinical Autonomic Research Society, Oxford

- 1989 Special Research Lecture, Am Soc Hypertension, New York
- 1989 State-of-the-Art Lecture, Interamer Congress Cardiology, Rio de Janeiro
- 1990 Presidential Lecture, Internat Soc Hypertension, Montreal
- 1990 State-of-the-Art Lecture, European Society Cardiology, Stockholm
- 1990 State-of-the-Art Lecture, World Congress of Cardiology, Manila
- 1991 State-of-the-Art Lecture, Internat Soc Hypertension, Rio de Janeiro
- 1991 State-of-the-Art Lecture, Internatl Soc Cardiovascular Pharmac, Geneva
- 1992 Clinical Conference for "Hypertension", Iowa City
- 1993 State-of-the-Art Lecture, European Society of Hypertension, Milan
- 1993 State-of-the-Art Lecture, Internat Soc Nephrology, Jerusalem
- 1993 Invited Lecture, Internat Meeting on Calcium Antagonists, Amsterdam
- 1993 Invited Lecture, European Society of Cardiology, Nice
- 1994 Invited Lecture, International Forum for Evaluation of Cardiovascular Care, Montecarlo
- 1995 Lecture, European Society of Pharmacology, Milan
- 1995 State-of-the-Art Lecture, European Soc Diabetology, EADS, Hamburg
- 1995 President Lecture, Canadian Society of Hypertension, Royal Society Physicians & Surgeons, Montreal
- 1995 Invited Debater, European Society of Hypertension, Milan
- 1996 Invited Lecture, International Forum for Evaluation of Cardiovascular Care, Montecarlo
- 1996 Invited Lecture, European Society of Cardiology, Birmingham
- 1996 Merck Frosst Lecture, Canadian Society of Medicine, Montreal
- 1997 Invited Lecture, European Society of Cardiology, Stockholm
- 1998 Invited Lecture, International Forum for Evaluation of Cardiovascular Care, Montecarlo
- 1998 Bjorn Folkow Lectura, European Society of Hypertension, Milan
- 1998 Invited Debater, International Society of Hypertension, Amsterdam
- 1998 Invited Lecture, American Society of Hypertension, New York
- 1999 Invited Lecture and Invited Debater, American Society of Hypertension, New York
- 1999 Invited Debater, European Society of Cardiology, Barcelona
- 1999 Invited Lecture, International Society of Cardiovascular Pharmacotherapy, Amsterdam
- 1999 Keynote Lecture, Clinical Autonomic Research Society, Bologna
- 1999 Invited Lecture, International Forum on Angiotensin II antagonists, Montecarlo
- 1999 State-of-the-Art Lecture, Interamerican Meeting on Hypertension, Buenos Aires
- 2000 Invited Lecture, International Forum for Evaluation of Cardiovascular Care, Montecarlo
- 2000 Invited Lecture, 1<sup>st</sup> Laragh Conference, ASH, Boca Raton
- 2000 Invited Lecture, Academia de Ciencias Medicas, Cordoba
- 2000 Invited Lecture, International Society of Hypertension, Chicago
- 2000 Invited Debater, European Society of Cardiology, Amsterdam
- 2001 Invited Lecture, International Society of Cardiovascular Pharmacotherapy, Kyoto
- 2001 Invited Lecture, Japanese Circulation Society, Kyoto
- 2001 Invited Lecture, International Forum on Angiotensin II Antagonists, Montecarlo
- 2001 Invited Lecture, International Congress on Preventive Cardiology, Osaka
- 2002 Invited Lecture, International Forum for Cardiovascular Care, Montecarlo
- 2002 State-of-the-Art Lecture, International Society of Hypertension, Prague
- 2002 State-of-the-Art Lecture, International Society of Cardiovascular Pharmacotherapy, Montreal
- 2002 Invited Lecture, International Congress of Internal Medicine, Kyoto
- 2002 State-of-the-Art Lecture, World Congress of Cardiology, Sydney
- 2002 Heymans Lecture, University of Ghent
- 2002 Invited Lecture, European Society of Cardiology, Berlin
- 2002 Invited Lecture, WHL/NHLBI Meeting on Obesity
- 2003 Invited Lecture, 3th Laragh Conference, ASH, Boca Raton
- 2003 Pickering Lecture, British Hypertension Society, Cambridge
- 2004 State-of-the-Art Lecture, International Society of Hypertension, Sao Paulo.
- 2004 State-of-the-Art Debater, International Society of Hypertension, Sao Paulo
- 2004 State-of-the-Art Lecture, European Society of Hypertension, Paris
- 2004 Invited lecture, International Forum for Evaluation of Cardiovascular Care, Montecarlo
- 2004 Invited Lecture, Fondazione Lorenzini, Drugs Affecting Lipid Metabolism, Venice
- 2005 Invited Debater, American Society of Hypertension, San Francisco
- 2005 Briant Bronte Memorial Lecture, university of Glasgow, Glasgow
- 2006 Invited Lecture, American Society of Hypertension, New York
- 2006 Invited Lecture, International Society of Hypertension, Fukuoka
- 2006 Invited Lecture, European Society of Hypertension, Madrid
- 2007 Invited Lecture, International Forum for Evaluation of Cardiovascular Care, Montecarlo
- 2007 Invited Lecture, European Society of Hypertension, Milan
- 2007 Invited Lecture, American Society of Hypertension, Chicago

- 2007 Invited Lecture, European Society of Hypertension, Milan
- 2007 State-of-the-Art Lecture, European Society of Cardiology, Vienna
- 2007 Invited Lecture, International Society of Nephrology, Nexus Meeting, Vienna
- 2008 State-of-the-Art Lecture (Plenary Session), ISH/ESH Meeting, Berlin.
- 2006 Franz Volhard Lecture, International society of Hypertension, Fukuoka
- 2008 State-of-the-Art Lecture, World Congress of Cardiology, Buenos Aires.
- 2008 Invited Lecture, American Society of Hypertension, New Orleans.
- 2009 Invited Plenary Lecture, American Society of Hypertension, New Orleans.
- 2009 Invited Lecture, Controversies to Consensus in Diabetes, Obesity and Hypertension, Barcelona
- 2009 State-of-the-Art Lecture, World Congress of Nephrology, Milan
- 2009 Invited Lecture, International Conference of Diabetes, Dyslipidemia and Hypertension, Valencia
- 2009 Invited Lecture, American Society of Hypertension, San Francisco
- 2009 State-of-the-Art Lecture, European Society of Hypertension, Milan
- 2009 - Invited Lecture, First Panarab Congress of Cardiology, Beirut
- 2009 Invited Lecture, European Society of Cardiology, Stratification of CV risk, Barcelona
- 2009 Invited Lecture, ESC-Asia Symposium, Beijing
- 2010 Invited Lecture, Debate, European Society of Hypertension, Oslo
- 2010 Invited Lecture, European Society of Cardiology, Stockholm
- 2010 Invited Lecture, European Atherosclerosis Society, Hamburg
- 2010 State-of-the-Art Lecture, 10<sup>th</sup> Conference on Artery, Verona
- 2010 Invited Lecture, American Society of Hypertension, New York
- 2011 Invited Lecture, European Society of Hypertension, Milan
- 2011 Invited Lecture, Cardiovascular Summit, Barcelona
- 2011 Invited Lecture, European Society of Cardiology, Paris
- 2012 Leloir Nobel Laureate Lecture, Argentinian Society of Hypertension, Buenos Aires
- 2012 Invited Lecture, ACC California, Los Angeles
- 2012 State-of-the-Art Lecture, European Atherosclerosis Society, Milan
- 2012 Invited Debater, European Society of Hypertension, London
- 2012 Invited Lecture, European Society of Cardiology, Munich
- 2012 Invited Lecture, American Society of Hypertension, New York
- 2012 Invited Lecture, Controversies to Consensus in Diabetes, Obesity and Hypertension, Barcelona
- 2012 Memorial Lecture (Hisayama Study) of the Japanese Cardiology Society, Fukuoka
- 2012 State-of-the-Art Lecture, Japanese Society of Hypertension, Nagoya
- 2012 Invited Debater, International Society of Hypertension, Sydney
- 2012 Invited Lecture, American Society of Hypertension, New York
- 2013 State-of-the-Art Lecture, Latin American Society of Hypertension, Isla Margarita
- 2013 Invited Lecture, European Society of Cardiology, Amsterdam
- 2013 State-of-the-Art Lecture, European Society of Hypertension, Milan
- 2014 State-of-the-Art Lecture, International & European Society of Hypertension, Athens
- 2014 Invited Lecture, European Society of Cardiology, Barcelona
- 2014 Opening Lecture, Interamerican Society of Hypertension, S. Salvador
- 2014 State-of-the-Art Lecture, Cardiosummit, Cancun
- 2014 Invited Lecture, American Heart Association Meeting, Chicago
- 2014 State-of-the-Art Lecture, Conference on Prehypertension and Cardiometabolic syndrome, Prague
- 2014 Invited Lecture, ESC Working Group, Prague
- 2014 State-of-the-Art Lecture, Japanese Hypertension Society, Tokio
- 2014 Invited Lecture, Cardiology, Diabetes, Nephrology. At the limits, London
- 2014 Invited Lecture, Europrevent, Amsterdam
- 2014 Invited Lecture, University of Glasgow
- 2015 Invited Lectures, European Society of Cardiology, London
- 2015 State-of-the-Art Lecture, First Gulf Hypertension Conference, Dubai
- 2016 Invited Lectures, Second Gulf Hypertension Conference, Dubai
- 2016 Mac Donald Lecture, Mac Master University, Hamilton (Canada)
- 2016 Population Health Lecture, Mac Master University, Hamilton (Canada)
- 2016 Plenary Lecture, International Society of Hypertension, Seul
- 2016 State-of-the-Art Lecture, European Society of Hypertension, Paris
- 2016 Invited Lecture, European Society of Cardiology, Rome
- 2017 Invited Lecture, European Society of Hypertension, Milan
- 2017 Invited Lecture, European Society of Cardiology, Barcelona
- 2017 Chair, AHA/ACC Official Hypertension Guidelines presentation, AHA, Anaheim
- 2018 Plenary Lecture, Asian Pacific Society of Cardiology, Taipei
- 2018 Plenary Lectures and Debates, European Society of Hypertension, Barcelona
- 2018 Invited Lecture, ERA-EDTA Meeting, Copenhagen

- 2018 Plenary Lectures and Debates, European Society of Cardiology, Munich
- 2018 Invited Lecture, Russian Society of Cardiology, Moscow
- 2018 Invited Lecture, International Society of Hypertension, Beijing
- 2018 Plenary Lecture, Latin American Society of Hypertension, Cartagena
- 2018 Plenary Lecture, International Congress on Hypertension in children and adolescents, Valencia
- 2019 Plenary Lecture, European Society of Hypertension, Milan
- 2019 Plenary Lecture, Japanese Society of Hypertension, Tokio
- 2019 Plenary Lecture, Meeting of the Taiwan Society of Cardiology
- 2019 Plenary Lecture Meeting of the Società di Cardiologia Latino-Americana, Cancun
- 2019 Invited Lecture, Annual Conference of the Cardiological Society of India, Delhi

## **8. OTHER SELECTED INVITED LECTURES**

- Minister of Health, Georgia Republic, Tblisi (1986)
- Japanese Society of Angiology, Kyoto (1989)
- Southern African Hypertension Society, Durban ( 1989, 2007)
- Spanish Hypertension League, Madrid (1986) ( Santiago 1994)
- Federation of the Brazilian Societies for Experimental Biology, Caxambu(1988)
- IFECC, Lisbona (1991,2010),Montecarlo 1992,1994,1996,1998,2000,2002,2004,2006,2008)Prague (2011), Nizza (2012) ,Budapest (2013)
- Swedish Hypertension League, Stockholm(1989,2006,2007)Fare cosi per le voci seguenti
- Argentinian Societyof Cardiology, Buenos Aires (1987 and 1992)
- Lebanese Hypertension League (2009, 2011)
- German Hypertension League, Heidelberg (1985) Berlin ( 2011)
- Danish Hypertension Society, Nyborg (1994) and Copenhagen (2000)
- Swedish Society of Hypertension, Stockholm (1985)
- Belgian Society of Cardiology, Bruxelles (1993, 2002)
- Portuguese Society of Cardiology, Coimbra (1995), Porto (1997), Lisbon(2006), Algarve (2007)
- French Society of Cardiology, Paris (1992,1994,2001,2005,2006,2008,2011)
- Japanese Society of Hypertension, Tokyo (1991)
- Korean Society of Internal Medicine, Seul (1991)
- Egyptian Society of Cardiology, Cairo (1991, 2010)
- Hellenic Society of Cardiology, Athens (1991) and Salonicco (1993)
- Brazilian Society of Cardiology, Sao Paulo (1991, 2012)
- Swiss Hypertension League, Stein am Rhein (1988)
- Finnish Society of Hypertension, Helsinki (1993, 2001)
- Hungarian Society of Hypertension, Budapest (1993,1999,2006,2007,2008,2009,2010,2011,2012)
- Slovenian Society of Hypertension, Lubiana (1995, 2002, 2010)
- Spanish Society of Hypertension and League, Madrid, Murgis, Valencia, Barcellona (1993, 1996, 1999, 2001, 2002, 2003, 2004, 2005,2006,2007,2008,2009,2010,2011,2012)
- International Forum on Angiotensin receptor antagonists, Montecarlo (1999,2001,2003,2005,2007,2009)
- Spanish Society of Cardiology, Tenerife (1991)
- Chinese Society of Cardiology, Taipei (1991)
- Incor Lecture (Heart and Lung Institute), Sao Paulo (1990)
- Chilean Societyof Cardiology, Santiago (1995)
- Argentinian Societyof Hypertension, Rosario (1995), Bariloche (2000), Buenos Aires (2012), Rosario (2013)
- Brazilian Society of Hypertension, Sao Paulo (1996)
- Catalan Society of Hypertension, Barcelona (2002,2007)
- Russian Society of Cardiology, Moscow (2003)
- American College of Cardiology, New Orleans (2004)
- Polish Society of Hypertension, Warsaw (2004, 2008, 2010)
- Portuguese Society of Cardiology (2005,2008)
- Cardiology Update Teaching Faculty, Davos (2001,2003,2005,2007,2009)
- German Hypertension Society, Hannover (2004,2011)
- Singapore Cardiology Society (2005)
- Malaysian Society of Cardiology (2005)
- Onassis Cardiology Canter, Athens (2006)

- Hellenic Society of Hypertension, Rhodes (2007),Athens (2011,2013)
- Estonian Society of Hypertension, Tallin (2007)
- Chinese Society of Cardiology, Beijing (2007)
- Mediterranean Meeting on Hypertension, Marmara, Istanbul, Antalya, Fetyie, Ismir, Antalya (1996,1998,2000, 2002, 2003, 2004, 2005, 2006, 2007,2008,2009,2010,2011,2012)
- Slovakian Society of Hypertension, Bratislava (2009)
- Hellenic Society of Hypertension, Athens, Thessaloniki, (2009,2010,2011,2012, 2013, 2014)
- Croatian Society of Hypertension, Zagreb (2010)
- Serbian Society of Hypertension, Belgrad (2012,2015,2016)
- Peruvian Society of Cardiology, Lima (2013 )
- Venezuela Society of Hypertension, Isla Margherita (2014)
- Pan-Hellenic Congress on Hypertension (2013)
- Chinese Hypertension League, Beijing, (2013,2014)
- Venezuelan Society of Hypertension, Isla Margarita (2013)
- Nigerian Society of Cardiology, Nairobi (2013)
- Cardioevent,Florence (2011,2012,2013,2014,2015,2016)
- Middle East Forum,Rome (2012), Istanbul (2013),Prague (2014)
- Slovenian Society of Hypertension, Lubiana (2011, 2012)
- Romanian Society of Hypertension, Iasi (2012), Bucharest (2013,2014)
- Brazilian Society of Cardiology, Biolab Congress, Florianopolis (2013)
- Korean Society of Interventional Cardiology,Seul (2014)
- Malaysian Society of Hypertension, Kuala Lumpur (2014)
- Taiwan Society of Cardiology,Taipei (2014)
- Oman Cardiology Society, Muscat (2014)
- Philippines Heart Association, Manila (2014)
- Azerbaijan Cardiology Society, Baku (2014)
- Bulgarian Cardiology Society, Sofia (2015)
- Resistant Hypertension Course, Berlin (2014,2015)
- CAD Conference, Indian Cardiology Society (2015)
- International Forum for evaluation of CV care, Dubai (2017)
- Indo-European Collaboration meeting, Mumbai (2017)
- ESH Summit, Gdansk (2017)
- Master Course on Hypertension (LASH/ESH),San Salvador (2017)
- Croatian Society of Hypertension, Dubrovnik (2017)
- ESC WG on microcirculation,Sinaia (2017)
- Taiwan Society of Cardiology, Taipei (2017)
- Hellenic Society of Cardiology, Athens (2018)
- Tunisian Society of Cardiology, Tabarka (2018)
- European Forum on Hypertension, Gdynia (2018)
- Asian Pacific Cardioconnect Meeting, Bali (2018)
- Romanian Society of Hypertension, Bucharest (2018)
- Spring School ESH-CHL,Beijing (2018)
- Vietnamese Society of Cardiology, Ho-Chi-Ming (2018)
- Korean Society of Hypertension, Seul (2018)
- Prehypertension and Metabolic Syndrome, Venice (2018)
- Meeting of the Minds, Sao Paulo (2018)
- International Congress on Hypertension in Children/Adolescents, Valencia (2018)
- Mc master International Course of Internal Medicine, Krakow (2019)
- Cardiology update, Davos (2019)Space, Brussels (2019)
- Train the Trainer (Royal College of Physicians) (2019)
- Cardioconnect Asian-Pacific Meeting, Ho Chi Minh (2019)
- ESC Meeting, Paris (2019)
- Meeting of the Indo-European Hypertension Collegium, Kolkata (2019)
- Top on Hypertension,Mumbai (2019)
- Meeting of the Hellenic Society of Cardiology,Athens (2019)
- Meeting of the Czeck Society of Cardiology, Brno (2019)
- Meeting of the Argentinian Society of Hypertension, Mar de la Plata (2019)
- Meeting of the Rumenian Society of Hypertension, Bucharest (2019)



## 9. JOURNALS SUPPLEMENTS (EDITOR)

- *Ambulatory Blood Pressure Monitoring*, Hypertension
- *Clinical Experimental Hypertension 1985*, A7.1-467
- *Sympathetic Nervous System in Hypertension*, J Hypertens 1985, 3, Suppl. 4, S1-S105
- *Regional Hemodynamics in Hypertension*, J Cardiovasc Pharmacol, 1987, 10, suppl. 5, S1-S136
- *Hypertension into the Nineties*, Am J Cardiol 1988, 61, Suppl 5, 1C-59C
- *Smoking and Cardiovascular Disease*, Am Heart J 1987, 115: 239-296
- *Calcium antagonists and CV disease: rationale for 24h action*, J Cardio Pharmacol, 1988, 12, Suppl 7, S1-S114
- *Therapeutical potential of third generation beta-receptor blockers*, J Cardio Pharmacol 1989, 14, Suppl 7, S1-S44
- *Angiotensin converting enzyme inhibition and hypertension*, Curr Op Cardiol 1989, 4, Suppl 1, S1-S47
- *Advances in pathophysiology and management of hypertension*, Am J Hypertens 1987, 2, Part 2, 1S-99S
- *Sympathetic activity as a target of antihypertensive therapy*, Curr Op Cardiol 1989, n.4, Suppl 4, S1-S81
- *The role of multiple action agents in hypertension*, Eur J Clin Pharmacol 1990, n.38, Suppl 2, S77-S170
- *International Consensus Conference on indirect BP monitoring*, J Hypertens 1990, n.8, Suppl 6, S1-S141
- *The costs and benefits of CHD risk factor reduction*, American Heart Journal 1989, 119, n.3, part 2, 711-776
- *Coronary heart disease risk in hypertensive smokers*, J Hypertens 1990, 8, suppl 5: S1-S62
- *1<sup>st</sup> WHO/ISH Symp on "Prevention of Hypertension and CV Disease"*, Clin Exper Hypertens 1990, A12, 5: 693-956
- *Concomitant problems in hypertension patients: recent advances*, J Human Hypertens 1990, 4, Suppl 5: 1-46
- *Risk factor modulation with new generation vasodilating beta-blockers*, Am Heart J 1991, 121, 3, Part 2: 989-1032
- *Serotonin, thrombotic complications and hypertension*, J Cardio Pharmacol 1991, 17, Suppl 7: S1-S66
- *New aspects of calcium antagonists in treatment of hypertension*, J Cardio Pharmacol 1991, 18, suppl 5: S1-S32
- *Dihydropyridines and their future in hypertension*, J Cardio Pharmacol 1991, 18, Suppl 1: S1-S112
- *Mental stress as a trigger of CV events*, Hypertension 1991, 17, Suppl 3: III1-III81
- *Ambulatory blood pressure monitoring and cardiovascular risk factors*, J Hypertens 1991, 9, Suppl 3: S1-S85
- *2<sup>nd</sup> WHO/ISH Symp on Prevention of Hypertension and CV Disease*, Clin Exper Hypertens 1992, A14: 1-341
- *Hypertension and Receptors*, Pharmacology and Toxicology 1992, 70: S1-S40
- *Hypertension. Contribution of Trandolapril, a new ACEI toward patient protection*, Am J Cardiol 1992, 70: ID-66D
- *Short- and long-term goals in the treatment of hypertension*, Am J Hypertens 1993, 6: 1S-115S
- *Transdermal clonidine. A new approach in the management of hypertension*, Clin Auton Research 1993, 3: 356-505
- *Recent advances on ACEI in treatment of hypertension and heart failure*, Am J Cardiol 1993, 71: 1E-68E
- *Kinetic and dynamic profile of dihydropyridine CCBs*, Res and Clin Forms, Wells Medical England 1994, 16, 1: 1-85
- *The Therapeutic Trials - Curr Hypertens Rep 2005*, 7: 273-303
- *The Therapeutic Trials - Curr Hypertens Rep 2006*, 8: 307-351
- *The Therapeutic Trials - Curr Hypertens Rep 2007*, 9: 315-356
- *The Therapeutic Trials - Curr Hypertens Rep 2008*, 10, 249-336
- *The Therapeutic Trials - Curr Hypertens Rep 2009*, 11, 235-297
- *The Therapeutic Trials - Curr Hypertens Rep 2010*, 12: 290-295
- *The Therapeutic Trials - Curr Hypertens Rep 2011*, 13: 303-308
- *The Therapeutic Trials - Curr Hypertens Rep 2012*, 14: 333-338
- *CCBs in Prevention of CV Diseases- High Blood Pressure & Cardiovascular Prevention*. 2009, Vol 16, 1, 1- 45.
- *Calcium antagonist therapy and end organ damage*, J Cardio Pharmacol 1994, 24, suppl 4: S1-S44
- *Treatment of Hypertension & Focus on prevention of late CV complications*. J Hypertens 1994; 12, Suppl. 5: S1-S43
- *Reducing CV risk: ONTARGET – a new standard in CV protection*. J Hypertens 2009, Vol. 27 Suppl. 5.
- *Trough to peak ratio: relevance to treatment of hypertension*, J Hypertens 1994, 12, suppl 5: S
- *Health-economic issues in cardiovascular disease*, European Heart Journal 1996, 17, suppl A: 1-4
- *Third WHO/ISH Meeting in "Prevention of hypertension and CV disease"*, Clin Exper Hypertens, 1996, 18; 1-593
- *Intervention trials in Hypertension, present and future*, J Hypertens 1996, 14, suppl. 2; S1-S141
- *The therapeutic role of CCBs: current evidence and future prospects*, J Hypertens 1996, 14, suppl. 4: S1-S41
- *A pharmacodynamic and clinical profile of amlodipine*, Clinical Drugs Invest 1997, 13, suppl. 1: 1-168
- *INSIGHT*, Intern J Clin Practice 1997, suppl. 92, 1-76
- *Evaluation of end points in Hypertension*, Blood Pressure 1997, suppl. 2, 3-123
- *Combination Therapy and vulnerable hypertensive pts*, J Cardiovasc Pharmacol 1997, 31, suppl. 2, S1-S44
- *Are European hypertensives getting optimal treatment?* Intern J Clin Practice 1998, suppl 98, 1-20
- *Endothelial function and CV disease in humans*, J Hypertens 1998, 16, suppl. 1, S1-S110
- *Blood Pressure burden: vascular changes and cerebrovascular complications*, J Hypertens 2000, 18, suppl. 1, S1-S2
- *Clonidina: attualità e prospettive nel nuovo millennio*, Excerpta Medica 1999, 1-143
- *Cardiovascular Drug Therapy (Ed italiana)*, Pensiero Scientifico Torinese, 1999, 1-1707
- *The do's and the don'ts when using All Receptor antagonists*, J Human Hypertens 2000, 14, suppl. 2, S1-S4
- *The therapeutic trials*, Curr Hypertens Rep 2001, 3 : 331-366

- *Cardiovascular clinical samples. Specific treatment strategies*, PAN Communications, Richmond, UK 2002: 1-252
- *The Therapeutic Trials*. Current Hypertension Reports 2002, 4: 319-332
- *High risk pts and multifactorial treatment*, Am J Cardiol 2007, 100, J1-J61
- *La Cirrosi epatica e le sue complicitanze*, J Medical Books, Viareggio, 2002 :1-177
- *Practical implications and implementation of PROGRESS*, J Hypertens 2003: S1-S29
- *5<sup>th</sup> WHO/ISH Meeting on Hypertension and CV Disease*, Clin Exper Hypertens 2004, 26, 593-761
- *ESH/ESC Guidelines for hypertension: implementation in daily clinical practice* Adis Int.2004, 12, Special issue 1:1-11
- *A new dawn in CV protection II: end-organ protection in high-risk patients*. J Hypertens 2005,23, suppl.1, S1
- *Antihypertensive Treatment and New-onset Diabetes Mellitus*. Curr Hypertens Rep 2005, 7:298-303
- *Guiding Antihypertensive Treatment Decision Using Ambulatory Blood Pressure Monitoring*. Curr Hyperten Rep.
- *Antihypertensive treatment: which endpoints to consider?*. Nephrol Dial Transplant (2005) Editorial Comment
- *Pulse pressure and CV Protection with Preterax in Hypertensive Diabetic Pts*, J Hypertens 2006, 24 Suppl3, 1-27
- *Management of Diabetic Hypertensive Pts:a Striking Advance with Preterax*, J Hypertens 2009,27, Suppl 1, 1-23
- *A New Dawn in CV protection:Blood Pressure Lowering through AT1 Blockade*. J Hyprtens 2003,21, Suppl.6, 1-46
- *Reducing CV Risk:ONTARGET-a New standard in CV Protection*. J Hypertens, 2009,27, Suppl 5, 1-40
- *ADVANCE:a New Era in Diabetes and Hypertension*. J Hypertens 2008,26, Suppl 2, 1-18
- *ADVANCE in the Prevention of CV Disease in Diabetic Patients*. Am J Hypertens 2007,20:15-225
- *Olmesartan/Amlodipina*. Medicinae Doctor, 2011, XVIII, 10:1-59
- *Hypertension Compendium*. Circulation Reserach 2015, 116:923-1095c
- *Hypertension Compendium* Circulation Research 2019, 124, 967-1140

#### 10. BOOKS/MONOGRAPHS (EDITOR)

- Hypertension Manual. Curchill Livingstone, London, 2002;1-706.
- Blood Pressure and Heart Rate variability – Computer analysis, methodology and clinical applications. IOS Press, Amsterdam. 1993;1-277
- The Metabolic Syndrome. A Therapeutic Challenge. Van Zuiden Communications. 2005:1-80
- Computer Analysis of the Cardiovascular Signals. IOS Press, Amsterdam. 1995:1-315
- The Metabolic Syndrome. A Therapeutic Challenge. 2<sup>nd</sup> Ed. Van Zuiden Communications. 2007:1-99
- Angiotensin II receptor antagonists in perspective. Martin Dunitz, London. 2000:1-175
- Angiotensin II receptor antagonists. Current perspectives. 2<sup>nd</sup> Ed. Informa Healthcare, Oxford. 2006:1-218
- Geneesmiddelen en het Metabole Syndrom. Van Zuiden Communications, Amsterdam. 2004:1-60
- Il Punto su Cuore e Ipertensione. OIC Medical Press, Firenze. 1989:1-191
- Novità Terapeutiche nell'Ipertensione Arteriosa. Fondazione Lorenzini, Milano. 1995:1-90
- Pharmacological Control of Calcium and Potassium Homeostasis. Kluwer, Dordrecht. 1995:1-273
- L'Ipertensione Arteriosa. Il Contributo della Ricerca Italiana. Scientific Press, Firenze. 2007:1-513.
- Manual of Hypertension of the European Society of Hypertension. Informa Healthcare, London. 2008:1-385
- Textbook of Hypertension, Pathophysiology, Elsevier, Amsterdam. 1997: 1-1102
- Clinical Cases in Hypertension. Specific Treatment Strategies. Excerpta Medica, Almere. 1998:1-193
- Frequenza Cardiaca. Significato Clinico nelle Malattie Cardiovascolari. Mediserve, Milano. 1999:1-54
- Ipertensione, Obesita e Dismetabolismo Primula Multimedia, Pisa. 2006:1-45
- Il monitoraggio della Pressione Arteriosa nelle 24 Ore. Primula Multimedia, Pisa. 2002:1-45
- Ipertensione Arteriosa, Rischio Cardiovascolare e Terapia di Associazione. Mediamed, Milano. 2007:1-192
- La misurazione della Pressione Arteriosa. Dal Laboratorio Sperimentale alla Pratica Clinica. Momento Medico, Salerno. 2001:1-131
- Special Issues in Hypertension. Springer, Milano. 2012:1-477
- Menopausa. Una Visione Multidisciplinare. Mediserve, Milano: 1997:1-152
- Profilo Clinico dell'Olmesartan alla Luce delle Linee-Guida 2007. Centro Scientifico Editore, Torino. 2008:1-202
- Cardiorenal Syndrome. Mechanisms, Risk and Treatment. Springer, Milano. 2010:1-396.
- Methodology and Clinical Applications of BP and Heart Rate Analysis. IOS Press, Amsteram. 1999:1-209
- Frontiers of Blood Pressure and Heart Rate Analysis. IOS Press, Amsterdam. 1997:1-263.
- L'Ipertensione Arteriosa. Il Contributo della Ricerca Italiana, Kurtis, Milano 2000, 1-592
- Hypertension and Organ Damage. An update in year 2000. Legatoria Industriale Mediterranea. 2001:1-179
- Multidisciplinarieta nel Trattamento del Paziente Iperteso. Sinergie, Milano. 2007:1-128.
- The Metabolic Syndrome. Full Guide. Momento Medico, Salerno. 2006:1-80
- Monitoraggio del rischio CV in Lombardia, Regione Lombardia 1985-1994, 1-95
- Combinazioni farmacologiche nell'ipertensione, Sinergie, Milano, 2019, 1-91

- The Sympathetic Nervous System and Cardiovascular Disease. Via Medica, Gdansk. 2008:1-94
- Manual of Hypertension of the European Society of Hypertension. 2<sup>nd</sup> Ed. CRC Press, New York: 2014:1-617
- White Coat Hypertension. An Unresolved Diagnostic and Therapeutic Problem Springer, Milano. 2014: 1-147
- Resistant Hypertension. Epidemiology, Pathophysiology, Diagnosis, Treatment. Springer, Milano. 2013: 1-195
- Assessment of Preclinical and Clinical Organ Damage in Hypertension. Springer, Milano. 2015: 1-218
- Arterial Disorders in Hypertension. Springer, Milano. 2015:1-431.
- Hypertension, Atherosclerosis and Lipids, Royal Society of Medicine, London, 1992, 1-94
- Interventional therapies for secondary and essential hypertension, Springer, Milano, 2016, 1-361
- New Concepts in stroke. Diagnosis and treatment. Bentham Science Publisher, Shariyah, UAE 2017:1-337
- Disorders of blood pressure regulation, Springer International, 2018:1-880
- Prehypertension and cardiometabolic syndrome, Springer International 2019:1-689
- Hypertension and heart failure, Springer International 2019: 1-416
- Thirty years of ESH (1989-2019), Creative Point, Athens, 2019:1-147
- Manual of Hypertension of the European Society of Hypertension, CRC/ Francis & Taylor, 2019:1-650
- Home Blood Pressure Monitoring, Springer International, 2019, 1-174

#### **11. CURRENT/PAST MAJOR EDITORIAL BOARD PARTICIPATION**

- Journal of Hypertension ( Current Chief Editor/Past Deputy Editor)
- Clinical Science (Specialist Editor)
- High Blood Pressure & Cardiovascular Prevention (Chief Editor)
- New in Physiological Sciences (Associate Editor)
- ISH Hypertension News ( Chief Editor)
- Cardiovascular Drugs & Therapy (Specialist Editor)
- Hypertension
- American Journal Hypertension
- Journal of Clinical Hypertension
- Clinical & Experimental Hypertension
- European Heart Journal
- Journal of Autonomic Nervous System
- Clinical Cardiology
- SNS Report (Editor in Chief)
- Current Hypertension Reports (Section Editor)
- Journal American Society of Hypertension
- Cardiovascular Research
- Nutrition, Metabolism & Cardiovascular Disease
- Blood Pressure
- Journal Cardiovascular Pharmacology
- Hypertension Research
- Journal of Clinical Metabolism & Diabetes
- Blood Pressure Monitoring
- Lancet (Reviewer)
- Circulation (Guest Editor)
- New England J of Medicine (Reviewer)
- Journal of the American College of Cardiology (Guest Editor)
- Hypertension Research
- British Medical Journal (Reviewer)
- Journal Internal Medicine and Patient Care
- American J Physiology (Reviewer)
- Journal Applied Physiology (Reviewer)
- Circulation Research (Guest Editor)
- Clinical Autonomic Research (Reviewer)
- Drugs
- Cardiovascular System
- Medical Research and Innovations
- EC Cardiology

- International J Research and Clinical Trials
- Giornale Italiano di Cardiologia
- International J Cardiology
- Austin J Sleep Disorders
- J Cardiovascular Diseases
- Pulmonary & Respiratory Medicine
- Diabetes & Endocrinology
- Heart & Vascular Medicine.
- Annals of Atherosclerosis & Thrombosis
- Circulation Research (Guest Editor)

## **12. MAJOR RESEARCH INTERESTS/RESEARCH AREAS**

GM's research has focused on the epidemiology, pathophysiology, diagnosis, treatment and prevention of hypertension, heart failure, coronary disease as well as on the pathophysiology and clinical aspects of obesity, diabetes, metabolic syndrome and other metabolic abnormalities. He devised and conducted the PAMELA study (the only population study with office/home and ambulatory blood pressure measurements), and has been Chairman or member of the Steering Committee of several major trials on hypertension ( ELSA/PHYLLIS/HOT/INVEST/APOLLO/VALUE/ONTARGET-TRANSCEND//ADVANCE/ADVANCE-ON/PROGRESS/SAMPLE). He has been member of the Writing Committee of several guidelines on hypertension and cardiovascular prevention (WHO/ISH/ESC/ACC/WHF) and has chaired the ESH/ESC Task Force on hypertension guidelines in 2003/2007/2009/2013/2018. His specific areas of expertise are the following:

- Reflex and central control of the circulation in health and disease
- Ambulatory/Home Blood Pressure Monitoring (mechanistic/diagnostic and clinical studies)
- Blood Pressure Variability (long/short term): epidemiological/diagnostic and therapeutic aspects
- Computer analysis of the cardiovascular signals
- Arterial mechanical properties
- Neurohumoral alterations (sympathetic activation/ baro-cardiopulmonary reflex abnormalities) in health and disease
- Obesity, Diabetes, Dyslipidemia and other Metabolic abnormalities
- Hypertension and Cardiovascular epidemiology
- Hemodynamic effects of cardiovascular drugs
- Clinical Trials in Hypertension and other Cardiovascular Diseases
- Smoking (BP effects and mechanisms of action)
- Invasive treatments in hypertension (baroreceptor stimulation & renal denervation)
- Stress/Sleep and the Cardiovascular system
- Organ damage ( cardiac/vascular/renal), including prognostic aspects
- "Real life" research on adherence/inertia to cardiovascular treatments (administrative data bases)

## **13. BIBLIOMETRIC DATA**

To 2019 GM has published more than 2000 original papers, reviews, editorials and consensus documents in "peer review" Journals. He is since many years in the list of the Highly Cited scientists of ISI and Clarivate Analytics. One of his papers has been the most highly cited article in the world medical literature in the years 2004-2005 (Ref. The Scientist) and three have been included among the most widely quoted hypertension papers ever (Ref. Hypertension, 2014). In 1995 he was classified as the most widely quoted cardiologist in Italy and in 2013 has been included among the 400 most influential biomedical investigators in the world ( Ref. Eur J Clin Inv). In 2019 he has been classified as the first expert in Europe and the second in the world for the area Hypertension-Cardiovascular (2008-2018 publications), Baltimore University, Ref. Expertscape). Recently, Plos Biology has classified him among the first 300 scientists in the world out of 6.8 million scientists analysed, 12<sup>th</sup> among world cardiologist and 1<sup>st</sup> among hypertensiologists. GM's

publications have received, up to April 2019, more than 201.000 citations in the international medical literature, with a H-index of 170 ( Ref. Microsoft Academy), the highest among Italian cardiologists and internists.

#### 14. MAIN SCIENTIFIC CONTRIBUTIONS

1. First description of blood pressure (BP)/cardiovascular (CV) changes as well as of their central, reflex, humoral and local mechanisms during REM sleep (free moving cats)
2. First description of BP/ CV changes (as well as of their central, reflex, humoral and local mechanisms) during emotional behaviours (free moving cats)
3. Demonstration of the “continuous” powerful inhibitory reflex control of sympathetic vasomotor tone by volume receptors in the heart (atria & ventricles) and lungs. Original demonstration in dogs, later extended to normotensive and hypertensive humans.
4. Demonstration of the “continuous” powerful reflex inhibition of renin release and renal vasomotor tone by cardiopulmonary receptors in dogs and humans.
5. First evidence of the powerful interaction between baroreceptors, chemoreceptors and cardiopulmonary receptors on CV control in dogs.
6. First evidence of the powerful baroreceptor influences on atrio-ventricular conduction in man ( His bundle recording) and of the masking effect on these influences of concomitant heart rate changes.
7. First description of carotid baroreceptor control of BP and the CV system via a newly devised neck chamber technique in healthy humans, primary hypertension and secondary hypertensions. Demonstration that in hypertension the baroreflex is selectively modified, an impairment of its heart rate component coexisting with an unimpaired BP control in the setting of an immediate and persistent upward resetting
8. Description of the timing, sensitivity and resetting of the carotid baroreceptor- blood pressure control during various acute and chronic antihypertensive treatments in man
9. Pioneer studies on i.a. ambulatory blood pressure monitoring with the first description and quantification of BP variability, its different components, its central and reflex determinants/its relationship with mean blood pressure within and between subjects, and its changes in normotensive, untreated and treated hypertensives.
10. Device and validation in animals and men of a technique based on computer analysis of the beat-to-beat EKG-BP signal that allows the arterial baroreflex involvement and sensitivity to be continuously assessed in daily life conditions, including the night time.
11. First evidence that in hypertension BP responses to natural stimuli are not only greater but also faster than in normotension throughout the day and night
12. Pioneer studies (via i.a. beat to beat and noninvasive BP measurements) on clinical aspects of ambulatory BP monitoring, with the first description of phenomena such as lack of placebo effect, high overall but poor hourly reproducibility, reproducibility and interrelationships of laboratory stressors, and white coat effect (magnitude, between patient differences, nurse vs doctor, persistence or decline over time, absence in unattended conditions, relationship with BP variability etc)
13. First demonstration that in treated hypertensives the inconsistency of BP control between visits has an independent adverse prognostic effect. Subsequent detailed description of the technical requirements for the measurement of visit-to-visit BP variability as well as of its limitations. Description of the prognostic importance of visit-to-visit BP variability in various clinical conditions and of its relative lower prognostic impact compared to mean on-treatment BP for CV and renal outcomes.
14. Description of the pressor effects of cigarette smoking on ambulatory BP as well as of the nicotine-dependant sympathetic activation via peripheral and central influences
15. Demonstration of the renin-angiotensin system-sympathetic nervous system excitatory interactions in the human coronary circulation.
16. First demonstration of seasonal BP changes by both office and ambulatory/home BP
17. First evidence (i.a. and non-invasive BP monitoring) of the superior predictive value of 24hour mean BP for cardiac damage and CV outcomes compared to office BP in hypertensives and the general population
18. First evidence that a therapeutic reduction of ambulatory BP predicts improvement of organ damage (regression of left ventricular hypertrophy) better than office BP

19. Description of prevalence, clinical characteristics, organ damage, determining mechanisms and prognostic significance of white coat and masked hypertension including, for white coat hypertension, the long-term BP effects of treatment.
20. Demonstration by microneurography of sympathetic activation and sympathetic baroreflex modulation in hypertension and heart failure before and during different treatments. For hypertension, evidence on early sympathetic activation, progressive sympathetic activation with BP increase and development of organ damage, and effects of drug treatment or lifestyle changes.
21. Demonstration of sympathetic activation and baroreflex impairment in obesity and other metabolic abnormalities as well as of their interaction with hypertension and reduction by diet.
22. Demonstration of sympathetic activation in a number of non-cardiovascular conditions (e.g. hepatic cirrhosis).
23. Demonstration of the sympathetic activation and baroreflex impairment associated by low salt diet in humans
24. Early mechanistic studies on arterial distensibility with the demonstration (arterial diameter/pressure relationship) on its modulation by sympathetic activity, exercise and alterations in diabetes and heart failure.
25. Clinical data from primary publications and/or subsequent post-hoc analyses of several major trials in hypertension: ELSA, INVEST, APOLLO, PHYLLIS, ONTARGET-TRANSCEND, PROGRESS, ADVANCE, ADVANCE-ON, VALUE, INSIGHT, HOT, SYSTEUR. The results have provided some of the best available evidence on threshold-target BP values for antihypertensive treatment, the clinical significance of treatment-induced changes in organ damage (renal and cardiac) the long-term effects of treatment on outcomes (<5 years), the prognostic significance of RAS blocker-dependant early changes in renal function etc
26. "Real life" research on hypertension, dyslipidemia, diabetes, via analysis of the large (>10 million individuals) Lombardy data-base, with evidence on adherence and therapeutic inertia patterns, determining factors and prognostic importance to antihypertensive drugs, antidiabetic drugs and statins. Evidence on role of above treatment at very old ages and in frailty people.

December, 2019